- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ligand Pharmaceuticals Incorporated (LGND)
Ligand Pharmaceuticals Incorporated stock price live, this page displays NASDAQ LGND stock exchange data. View the LGND premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ligand Pharmaceuticals Incorporated real time stock price chart below.
What Is the Ligand Pharmaceuticals Incorporated Stock Price Today?
The Ligand Pharmaceuticals Incorporated stock price today is 316.13.
What Is the Stock Symbol for Ligand Pharmaceuticals Incorporated?
The stock symbol for Ligand Pharmaceuticals Incorporated is "LGND."
What Stock Exchange Does Ligand Pharmaceuticals Incorporated Trade On?
Ligand Pharmaceuticals Incorporated is listed and trades on the NASDAQ stock exchange.
Is Ligand Pharmaceuticals Incorporated a Good Stock to Buy?
Determining whether Ligand Pharmaceuticals Incorporated—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LGND quote. (ISIN: US53220K5048)
What Is the Ligand Pharmaceuticals Incorporated Stock Price Today?
The Ligand Pharmaceuticals Incorporated stock price today is 316.13.
What Is the Stock Symbol for Ligand Pharmaceuticals Incorporated?
The stock symbol for Ligand Pharmaceuticals Incorporated is "LGND."
What Stock Exchange Does Ligand Pharmaceuticals Incorporated Trade On?
Ligand Pharmaceuticals Incorporated is listed and trades on the NASDAQ stock exchange.
Is Ligand Pharmaceuticals Incorporated a Good Stock to Buy?
Determining whether Ligand Pharmaceuticals Incorporated—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LGND quote. (ISIN: US53220K5048)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
309.86
319.99
52 wk Range
175.89
326.63
LGND is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
309.86319.99
52 wk Range
175.89326.63
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LGND Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
350.92
Upside
+11.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Form 144 LIGAND PHARMACEUTICALS INC For: 3 November- Investing.com
Form 144 LIGAND PHARMACEUTICALS INC For: 31 October- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 350.92
(+11.00% Upside)
Ligand Pharmaceuticals Incorporated SWOT Analysis
Royalty Powerhouse | Ligand's unique drug royalty aggregator model drives impressive growth, with a 73.59% stock return over the past year and a strong financial health score. |
Financial Triumph | Explore Ligand's robust financial performance, featuring a 78.77% gross profit margin and projected EPS growth from $2.44 in 2022 to over $10.00 by 2028. |
Pipeline Progress | Recent FDA approvals for Ohtuvayre and Capvaxive, along with EU approval for Filspari, showcase Ligand's development capabilities and future revenue potential. |
Analyst Optimism | Delve into analyst perspectives, with price targets ranging from $110 to $150, reflecting confidence in Ligand's diversified portfolio and growth strategy. |
Ligand Pharmaceuticals Incorporated Earnings Call Summary for Q3/2026
- Ligand Q3 adjusted EPS of $2.67 beat estimates by 16%, prompting raised full-year guidance to $9.50-$9.75 from $9.00-$9.50 previously.
- Royalty revenue surged 51% YoY to $70.3M, driven by legacy assets and XOMA acquisition; total revenue fell 9% to $78.75M due to prior-year one-time income.
- XOMA deal expanded financial royalty assets from $200M to $800M; company now holds 200+ commercial, clinical, and preclinical royalty assets.
- Management expects up to seven pivotal trial readouts through 2027, including QTORIN rapamycin FDA decision Feb 28, 2027, with potential $1B sales.
- Company maintains $270M-$310M 2026 revenue guidance; deployable capital stands at $750M with annual deployment below $200M expected to sustain growth.
Last Updated: 10/29/2026, 10:06 PM
Read Full TranscriptEarnings
Latest Release
Oct 29, 2026
EPS / Forecast
2.67 / 2.30
Revenue / Forecast
78.75M / 78.09M
Compare LGND to Peers and Sector
Metrics to compare | LGND | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLGNDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 122.9x | −14.5x | −0.2x | |
PEG Ratio | −30.88 | −0.09 | 0.00 | |
Price/Book | 6.6x | 2.6x | 2.6x | |
Price / LTM Sales | 24.9x | 3.8x | 2.8x | |
Upside (Analyst Target) | 11.0% | 91.7% | 62.7% | |
Fair Value Upside | Unlock | 11.9% | 8.0% | Unlock |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Ligand (LGND) Stock Price Today?
The Ligand stock price today is 316.13 USD.
What Stock Exchange Does Ligand Trade On?
Ligand is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Ligand?
The stock symbol for Ligand is "LGND."
What Is the Ligand Market Cap?
As of today, Ligand market cap is 6.32B USD.
What Is Ligand's Earnings Per Share (TTM)?
The Ligand EPS (TTM) is 2.60.
When Is the Next Ligand Earnings Date?
Ligand will release its next earnings report on Mar 04, 2027.
From a Technical Analysis Perspective, Is LGND a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Ligand Stock Split?
Ligand has split 1 times.
How Many Employees Does Ligand Have?
Ligand has 47 employees.
What is the current trading status of Ligand (LGND)?
As of Nov 05, 2026, Ligand (LGND) is trading at a price of 316.13 USD, with a previous close of 316.13 USD. The stock has fluctuated within a day range of 309.86 USD to 319.99 USD, while its 52-week range spans from 175.89 USD to 326.63 USD.
What Is Ligand (LGND) Price Target According to Analysts?
The average 12-month price target for Ligand is 350.92 USD, with a high estimate of 406 USD and a low estimate of 247 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +11.00% Upside potential.
What Is the LGND Premarket Price?
LGND's last pre-market stock price is 320.50 USD. The pre-market share volume is 730.00, and the stock has decreased by 6.98, or 2.23%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.